[Notices]
[Page 36811-36812]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr28jn06-94]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Public Notice
AGENCY: Centers for Disease Control and Prevention (CDC), Health and
Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC),
Coordinating Center for Infectious Disease (CCID), through its
component Centers and Divisions has lead technical responsibility for a
number of Category A, B and C bioterrorism agents and their associated
toxins (Bacillus anthracis, Clostridium botulinum, Brucella sps.,
Burkholderia sps., Staphylococcus entertoxin B, other food- or
waterborne bacterial pathogens, and other bacterial agents). CCID uses
epidemiologic, laboratory, clinical, and biostatistical sciences to
control and prevent bacterial and mycotic infectious disease. The
Centers also conduct applied research in a variety of settings, and
translate the findings of this research into public health practice.
The purpose of this announcement is to make interested parties
aware that CCID is currently engaged in a research activity to
establish and evaluate an intravenous infusion rabbit model for
delivery of therapeutic molecules for the treatment of inhalation
anthrax. The activity is in the early stage of feasibility assessment.
The protocols for these studies may be made available to interested
parties upon request. The short term objective of making these
protocols available is to promote standardization of the approach to in
vivo model development for anthrax therapy evaluation to meet the
Nation's bioterrorism defense needs. The longer term objective is to
develop these or subsequent protocols into standardized in vivo models
that may meet the Food and Drug Administration (FDA) acceptance
criteria for product development and licensure.
Interested organizations may request an electronic copy of the
protocols by contacting CDC at the address below. To ensure a response,
requests must be submitted within thirty days of publication of this
notice.
Responses are preferred in electronic format and can be e-mailed to
the attention of Dr. Conrad Quinn at CQUINN@CDC.GOV. Mailed responses
can be sent to the following address: Dr. Conrad Quinn, Division of
Bacterial Diseases, Coordinating Center for Infectious Diseases,
Centers for Disease Control and Prevention, 1600 Clifton Rd., NE., Mail
Stop C-09, Atlanta, GA 30333.
FOR FURTHER INFORMATION CONTACT:
Technical: Dr. Conrad Quinn, Division of Bacterial and Mycotic
Diseases, National Center for Infectious Diseases, Centers for Disease
Control and Prevention (CDC), 1600 Clifton Rd., NE., Mail Stop D-11,
Atlanta, GA 30333. Telephone (404) 639-2858, e-mail at CQUINN@CDC.GOV.
[[Page 36812]]
Business: Dr. Conrad Quinn, Division of Bacterial and Mycotic
Diseases, National Center for Infectious Diseases, Centers for Disease
Control and Prevention (CDC), 1600 Clifton R., NE., Mail Stop E-51,
Atlanta, GA 30333. Telephone (404) 639-2858, e-mail at CQUINN@CDC.GOV.
Dated: June 20, 2006.
James D. Seligman,
Chief Information Officer, Centers for Disease Control and Prevention.
[FR Doc. E6-10173 Filed 6-27-06; 8:45 am]
BILLING CODE 4163-18-P